ArticleAmerican journal of ophthalmology2023
Incidence of and Risk Factors for Cataract in Anterior Uveitis.
Article in American journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Reduced rates of intraocular surgeries in anterior uveitis.Acta ophthalmologica · 2026Article
- Dual-targeting VEGF and TNF-α with bispecific antibody eyedrops for synergistic treatment of uveitis.Journal of nanobiotechnology · 2026Article
- Viscosynechiolysis and Aspiration-Based Management in Uveitic Cataract Surgery: A Case Report.Cureus · 2026Article
- Impact of complications in adult anterior uveitis in a Finnish single-centre registry study.BMJ open ophthalmology · 2025Article
- Incidence and Outcome of Cataract in Eyes with Scleritis and Episcleritis.Ocular immunology and inflammation · 2025Article
- Advances in the management of uveitic cataract: current strategies and emerging perspectives.International ophthalmology · 2025Review
- Harnessing stem cell therapeutics in LPS-induced animal models: mechanisms, efficacies, and future directions.Stem cell research & therapy · 2025Review
- Comparative biocompatibility of hydrophilic vs. hydrophobic intraocular lenses following phacoemulsification in patients with uveitis.PloS one · 2025Article
- Safe Use of Corticosteroids in Non-Infectious Uveitis.Journal of inflammation research · 2025Review
- Cataract Development Among Pediatric Patients With Uveitis.JAMA network open · 2024Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 12 institutions in 3 countries.
Funding
Abstract
purposeTo estimate the incidence/risk factors for cataract in noninfectious anterior uveitis.
designRetrospective multicenter cohort study (6 US tertiary uveitis sites, 1978-2010).
methodsData were harvested by trained expert reviewers, using protocol-driven review of experts' charts. We studied cataract incidence-newly reduced visual acuity worse than 20/40 attributed to cataract; or incident cataract surgery-in 3923 eyes of 2567 patients with anterior uveitis.
resultsCataract developed in 507 eyes (54/1000 eye-years, 95% CI 49-59). Time-updated risk factors associated with cataract included older age (≥65 vs <18 years: adjusted hazard ratio [aHR] 5.04, 95% CI 3.04-8.33), higher anterior chamber cell grade (P(trend)=0.001), prior incisional glaucoma surgery (aHR 1.86, 95% CI 1.10-3.14), band keratopathy (aHR 2.23, 95% CI 1.47-3.37), posterior synechiae (aHR 3.71, 95% CI 2.83-4.87), and elevated intraocular pressure ≥30 vs 6-20 mm Hg (aHR 2.57, 95% CI 1.38-4.77). Primary acute (aHR 0.59, 95% CI 0.30-1.15) and recurrent acute (aHR 0.74, 95% CI 0.55-0.98) had lower cataract risk than chronic anterior uveitis. Higher-dose prednisolone acetate 1%-equivalent use (≥2 drops/day) was associated with >2-fold higher cataract risk in eyes with anterior chamber cell grades 0.5+ or lower but was not associated with higher cataract risk in the presence of anterior chamber cells of grade 1+ or higher.
conclusionsCataract complicates anterior uveitis in ∼5.4/100 eye-years. Several fixed and modifiable risk factors were identified, yielding a point system to guide cataract risk minimization. Topical corticosteroids only were associated with increased cataract risk when anterior chamber cells were absent or minimally present, suggesting their use to treat active inflammation (which itself is cataractogenic) does not cause a net increase in cataract incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.